ARWR (Arrowhead Research Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by ARWR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-17 | Matthew Gregory Cohen | Director | A | — | — |
| 2026-05-14 | Hongbo Lu | Director | Sell | — | — |
| 2026-04-24 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2026-04-24 | Daniel Joseph Apel | Chief Financial Officer | Sell | — | — |
| 2026-03-09 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2026-01-08 | Patrick O'Brien | COO | MIXED | — | — |
| 2026-01-08 | Daniel Joseph Apel | Chief Financial Officer | A | — | — |
| 2026-01-08 | James C Hamilton | Chief Medical Officer | A | — | — |
| 2026-01-05 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2026-01-05 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2026-01-05 | Patrick O'Brien | COO | MIXED | — | — |
| 2025-12-30 | Mauro Ferrari | Director | Sell | — | — |
| 2025-12-30 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | — |
| 2025-12-23 | ADEOYE Y OLUKOTUN | Director | Sell | — | — |
| 2025-12-23 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2025-12-23 | Victoria Vakiener | Director | Sell | — | — |
| 2025-12-23 | William D. Waddill | Director | Sell | — | — |
| 2025-12-19 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2025-12-18 | William D. Waddill | Director | A | — | — |
| 2025-12-18 | ADEOYE Y OLUKOTUN | Director | A | — | — |
| 2025-12-18 | DOUGLAS S INGRAM | Director | A | — | — |
| 2025-12-18 | Victoria Vakiener | Director | A | — | — |
| 2025-12-18 | MICHAEL S PERRY | Director | A | — | — |
| 2025-12-18 | Hongbo Lu | Director | A | — | — |
| 2025-12-18 | Mauro Ferrari | Director | A | — | — |
| 2025-12-16 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | — |
| 2025-12-09 | MICHAEL S PERRY | Director | Sell | — | — |
| 2025-12-01 | Mauro Ferrari | Director | Sell | — | — |
| 2025-10-03 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2025-09-16 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2025-09-04 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2025-08-15 | James C Hamilton | Chief Medical Officer | Sell | — | — |
| 2025-04-11 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2025-03-17 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | — |
| 2025-03-05 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | — |
| 2025-02-10 | Christopher Richard Anzalone | Chief Executive Officer | A | — | — |
| 2025-02-07 | DOUGLAS S INGRAM | Director | A | — | — |
| 2025-01-27 | ADEOYE Y OLUKOTUN | Director | Sell | — | — |
| 2025-01-07 | Kenneth Allen Myszkowski | Chief Financial Officer | MIXED | — | — |
| 2025-01-07 | Patrick O'Brien | COO and General Counsel | MIXED | — | — |
| 2025-01-07 | James C Hamilton | Chief Discovery/Trans Medicine | MIXED | — | — |
| 2025-01-06 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2024-12-30 | ADEOYE Y OLUKOTUN | Director | Sell | — | — |
| 2024-12-23 | Christopher Richard Anzalone | Chief Executive Officer | Sell | — | — |
| 2024-12-20 | Christopher Richard Anzalone | Chief Executive Officer | MIXED | — | — |
| 2024-12-20 | Hongbo Lu | Director | A | — | — |
| 2024-12-20 | MICHAEL S PERRY | Director | A | — | — |
| 2024-12-20 | Mauro Ferrari | Director | A | — | — |
| 2024-12-20 | William D. Waddill | Director | A | — | — |
| 2024-12-20 | ADEOYE Y OLUKOTUN | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 3,792,739 | — |
| — | Chief Operating Officer | 854,788 | — |
| — | Chief Financial Officer | 473,433 | — |
| — | COO | 472,848 | — |
| — | Chief Medical Officer | 226,958 | — |
| — | Chief Medical Officer | 206,000 | — |
| — | Snr. VP, Chem and Non-Clin Dev | 201,700 | — |
| — | VP, Strategic Bus. Initiatives | 194,375 | — |
| — | Chief Financial Officer | 162,905 | — |
| — | Director | 148,852 | — |
| — | Director | 137,214 | — |
| — | Chief Commercial Officer | 127,107 | — |
| — | Director | 123,059 | — |
| — | Chief Commercial Officer | 105,750 | — |
| — | Director | 69,053 | — |
| — | Director | 56,563 | — |
| — | Director | 52,012 | — |
| — | Director | 46,215 | — |
| — | Director | 42,964 | — |
| — | Director | 42,220 | — |
| — | Director | 33,600 | — |
| — | Director | 31,267 | — |
| — | 10%+ Owner | 24,158 | — |
| — | Chief Scientific Officer | 15,625 | — |
| — | Chief Scientific Officer | 15,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARWR quote page; the site-wide leaderboard is on the insider transactions hub.